DGIdb - IRBESARTAN Drug Record

IRBESARTAN chembl:CHEMBL1513 Approved

Alternate Names:

IRBESARTAN
SR-47436
KARVEA
APROVEL
SABERVEL
IFIRMASTA
BMS-186295
AVAPRO
2-BUTYL-3-{[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL}-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
BMS 186295
pubchem.compound:3749
rxcui:83818
chembl:CHEMBL1513
chemidplus:138402-11-6
drugbank:01029

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antihypertensive agent
Year of Approval	1997
Drug Class	antihypertensive agents

(4 More Sources)

Publications:

van den Meiracker et al., 1995, Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension., Hypertension
Dol et al., 2001, Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice., J. Cardiovasc. Pharmacol.
Adams et al., 2000, Irbesartan: review of pharmacology and comparative properties., Can J Clin Pharmacol
Mazzolai et al., 1999, Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists., Hypertension
Voigt et al., 2007, Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats., Eur. J. Pharmacol.
Morsing et al., 1999, Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin., Hypertension
Croom et al., 2004, Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy., Drugs
Martin et al., 2004, Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan., J. Cardiovasc. Pharmacol.
Hope et al., 1999, Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis., Am. J. Hypertens.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Waeber et al., 2003, AT1-receptor antagonism in hypertension: what has been learned with irbesartan?, Expert Rev Cardiovasc Ther
Croom et al., 2008, Irbesartan: a review of its use in hypertension and diabetic nephropathy., Drugs
Carraway et al., 1999, Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats., J. Cardiovasc. Pharmacol.
Choi CI et al., 2012, CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects., Eur J Clin Pharmacol
Hong X et al., 2005, CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population., Eur J Clin Pharmacol
Hallberg P et al., 2002, The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial., J Hypertens
Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens
Kurland L et al., 2004, Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial., Am J Hypertens
Kurland L et al., 2001, Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients., J Hypertens
Pons et al., 2003, Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure., J. Cardiovasc. Pharmacol.
Ortlepp JR et al., 2002, Variants of the CYP11B2 gene predict response to therapy with candesartan., Eur J Pharmacol
Fliegner et al., 2008, Up-regulation of PPARgamma in myocardial infarction., Eur. J. Heart Fail.
Taavitsainen et al., 2000, In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists., Eur. J. Clin. Pharmacol.
Hallberg P et al., 2004, Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol

IRBESARTAN AGTR1

Interaction Score: 2.15

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name irbesartan,Avapro, Irbetan

Novel drug target Established target

Mechanism of Interaction Type-1 angiotensin II receptor antagonist

PMIDs:
7843749 11486244 10822210 10082498 17408613 10373224 15101793 14716205 10075381 11752352 15030294 18627212 10069682

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
IRBESARTAN AGT

Interaction Score: 1.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15614026 14700505 11593098

Sources:
PharmGKB
IRBESARTAN EDN1

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15188945

Sources:
PharmGKB
IRBESARTAN APOE

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12827021

Sources:
NCI
IRBESARTAN APOB

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15614026

Sources:
PharmGKB
IRBESARTAN ACE

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11593098 12065207

Sources:
PharmGKB
IRBESARTAN SLC2A4

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18162196

Sources:
NCI
IRBESARTAN CYP2C9

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21842338 16094537 12359989

Sources:
PharmGKB
IRBESARTAN CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10877007

Sources:
NCI
IRBESARTAN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: IRBESARTAN
- Version: 01-August-2011
Alternate Names:

IRBESARTAN Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1997

Publications:
TdgClinicalTrial: IRBESARTAN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antihypertensive agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: IRBESARTAN

Version: 14-September-2017

Alternate Names:

C29130 NCI drug code

Drug Info:

Publications:

Fliegner et al., 2008, Up-regulation of PPARgamma in myocardial infarction., Eur. J. Heart Fail.

Pons et al., 2003, Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure., J. Cardiovasc. Pharmacol.

Taavitsainen et al., 2000, In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists., Eur. J. Clin. Pharmacol.

PharmGKB: irbesartan

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens

Hallberg P et al., 2004, Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol

Hong X et al., 2005, CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population., Eur J Clin Pharmacol

DTC: IRBESARTAN
- Version: 02-September-2020
Alternate Names:

CHEMBL1513 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Irbesartan
- Version: 2020.06.01
Alternate Names:

D00JAU TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1513
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1513
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	irbesartan,Avapro, Irbetan
Novel drug target	Established target
Mechanism of Interaction	Type-1 angiotensin II receptor antagonist

IRBESARTAN Drug Record

IRBESARTAN chembl:CHEMBL1513 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name irbesartan,Avapro, Irbetan Novel drug target Established target Mechanism of Interaction Type-1 angiotensin II receptor antagonist

PMIDs: 7843749 11486244 10822210 10082498 17408613 10373224 15101793 14716205 10075381 11752352 15030294 18627212 10069682

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15614026 14700505 11593098

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15188945

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12827021

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15614026

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11593098 12065207

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18162196

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21842338 16094537 12359989

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10877007

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: IRBESARTAN

Alternate Names: IRBESARTAN Primary Drug Name

Drug Info: Drug Class antihypertensive agents Year of Approval 1997

Publications:

TdgClinicalTrial: IRBESARTAN

Alternate Names:

Drug Info: Drug Indications antihypertensive agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: IRBESARTAN

Alternate Names: C29130 NCI drug code

Drug Info:

PharmGKB: irbesartan

Alternate Names:

Drug Info:

DTC: IRBESARTAN

Alternate Names: CHEMBL1513 ChEMBL Drug ID

Drug Info:

Publications:

TTD: Irbesartan

Alternate Names: D00JAU TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1513

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1513

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name irbesartan,Avapro, Irbetan

Novel drug target Established target

Mechanism of Interaction Type-1 angiotensin II receptor antagonist

PMIDs:
7843749 11486244 10822210 10082498 17408613 10373224 15101793 14716205 10075381 11752352 15030294 18627212 10069682

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
15614026 14700505 11593098

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15188945

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12827021

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15614026

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11593098 12065207

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18162196

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21842338 16094537 12359989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10877007

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

IRBESARTAN Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1997

Drug Info:

Drug Indications antihypertensive agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C29130 NCI drug code

Alternate Names:

CHEMBL1513 ChEMBL Drug ID

Alternate Names:

D00JAU TTD Drug ID